Association of arginine vasopressin and arterial blood pressure in a population-based sample

Journal of Hypertension

Volumn 17, Issue 3, 1999, Pages 319-324

  Zhang, Xun ^a   Hense, Hans Werner ^b,c   Riegger, Günter A J ^a   Schunkert, Heribert ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Arginine vasopressin; Arterial blood pressure; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; RENIN;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NORMAL HUMAN; PLASMA RENIN ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 0033018491     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917030-00003     Document Type: Article

References (35)

1. 1 Buijs RM. Vasopressin localization and putative functions in the brain. In: Gash DM, Boer GJ (editors): Vasopressin. Principles and properties. New York: Plenum Press; 1987. pp. 91-115.
2. 2 Gavras I, Gavras H. Role of vasopressin in hypertensive disorders. In: Laragh H, Brenner BM (editors): Hypertension: pathophysiotogy, diagnosis and management. New York: Raven Press; 1995. pp. 789-800.
3. 3 Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JIS. Changes of vasopressin in hypertension: cause or effect? Lancet 1976; 1:1255-1257.
4. 4 Crofton JT, Share L, Shade RE. Allen C, Tarnowski D, Vasopressin in the rat with spontaneous hypertension. Am J Physiol 1978; 235:H361-H366.
5. 5 Cowley AW Jr, Cushman WC, Quillen EW Jr, Skelton MM, Langford HG. Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension 1981; 3 (suppl I):I93-I100.
6. 6 Berecek KH, Barron KW, Webb RL, Brody MJ. Vasopressin-central nervous system interactions in the development of DOCA hypertension. Hypertension 1982; 4 (suppl II):II-131-II-137.
7. 7 Cowley AW Jr, Skelton MM, Velasquez MT. Sex differences in the endocrine predictors of essential hypertension: vasopressin versus renin. Hypertension 1985; 7 (suppl I):I151-I160.
8. 8 Os I, Kjeldsen SE, Skjoto J, Westheim A, Lande K, Aakesson I, et al. Increased plasma vasopressin in low renin essential hypertension. Hypertension 1986; 8:506-513.
9. 9 Ribeiro A, Mulinan R, Gavras I, Kohlmann O, Ramos O, Gavras H. Sequential elimination of pressor mechanisms in severe hypertension in humans. Hypertension 1986; 8 (suppl I):I169-I173.
10. 10 Crofton JT, Ota M, Share L Role of vasopressin, the renin-angiotensin system and sex in Dahl salt-sensitive hypertension. J Hypertens 1993; 11:1031-1038.
11. 11 Burrell LM, Philips PA, Stephenson JM, Risvanis J, Rolls KA, Johnston CI. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension 1994; 23:737-743.
12. 12 Cowley AW, Monos E, Guyton AC. Interaction of vasopression and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog. Circ Res 1974; 34:505-514.
13. 13 Morton JJ, Padfield PL. Vasopressin and hypertension in man. J Cardiovasc Pharmacol 1986; 8 (suppl 7):S101-S106.
14. 14 Padfield PL, Brown JJ, Lever AF, Morton JJ, Robertson JIS. Blood pressure in acute and chronic vasopressin excess. N Engl J Med 1981; 304:1067-1070.
15. 15 Lohmeier TE, Smith MJ Jr, Cowley AW Jr, Manning RD Jr, Guyton AC. Is vasopressin an important hypertensive hormone? Hypertension 1981; 3:416-425.
16. 16 Bussien JP, Waeber B, Nussberger J, Schaller MD, Gavras H, Hofbauer KG, et al. Does vasopressin sustain blood pressure of normally hydrated healthy volunteer? Am J Physiol 1984; 246:H143-H147.
17. 17 Thibonnier M, Aldigier JC, Soto ME, Sassano P, Menard J, Corvol P. Abnormalities and drug-induced alterations of vasopressin in human hypertension. Clin Sci 1981; 61:148s-152s.
18. 18 Robertson GL, Ganguly A. Osmoregulation and baroregulation of plasma vasopressin in essential hypertension. J Cardiovasc Pharmacol 1986; 8:S87-S91.
19. 19 Atkinson AB, Brown JJ, Davies DL, Fraser R, Leckie B, Lever AF, et al. Hyponatraemic hypertensive syndrome with renal-artery occlusion corrected by captopril. Lancet 1979; ii:606-608.
20. 20 Padfield PL, Morton JJ. Effects of angiotensin II on arginine-vasopressin in physiological and pathological situations in man. J Endocrinol 1977; 74:251-259
21. 21 Nishida N, Ogura T, Yamauchi T, Hosoya M, Ota Z. Treatment with cilazapril, angiotensin-converting enzyme inhibitor, changes the affinity of arginine vasopressin receptor in the kidney of the spontaneously hypertensive rat. Res Commun Chem Pathol Pharmacol 1994; 84:143-152.
22. 22 DelBo A, Suraci S, Giuditta M, Misto M, Zanchetti A. Effects of antihypertensive treatment on vasopressin secretion and on its osmoregulation in moderate hypertension. J Hypertens 1997; 15:1277-1283.
23. 23 Mayerson AB, Frishman WH. Vasopressin and vasopressin receptor antagonists in cardiovascular disease. In: Frishman WH, Sonnenblick EH (editors): Cardiovascular pharmacotherapeutics. New York, NY: McGraw-Hill; 1996. pp. 769-785.
24. 24 Keil U, Stieber J, Döring A, Chambless L, Härtel U, Filipartrik B, et al. The cardiovascular risk factor profile in the study area Augsburg: results from the first MONICA survey 1984/1985, Acte Med Scand 1988; 728 (suppl):119-128.
25. 25 Morton JJ, Riegger GAJ. A novel extraction method for plasma vasopressin and its application in a radioimmunoassay. J Endocrinol 1978; 77:277-278.
26. 26 Derkx FHM, deBruin RJA, Gool JMGV, Hoek MJCV, Beerendonk CCM, Rosmalem FMA, et al. Clinical validation of monoclonal renin antibody sandwich assays of renin and prorenin. Clin Chem 1996; 42:1051-1063.
27. 27 Schunkert H, Ingelfinger JR, Hirsch AT, Tang SS, Litwin S, Talness C, et al. Evidence for tissue specific activation of renal angiotensinogen mRNA expression in chronic stable heart failure. J Clin Invest 1992; 90:1523-1529.
28. 28 Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein C, Lorell BH. Increased rat cardiac angiotensin converting enzyme activity and mRNA levels in pressure overload left ventricular hypertrophy: effects on coronary resistance, contractility and relaxation. J Clin Invest 1990; 86:1913-1920.
29. 29 Rabito SF, Carretero OA, Scicli AG. Evidence against a role of vasopressin in the maintenance of high blood pressure in mineralocorticoid and renovascular hypertension. Hypertension 1981; 3:34-38.
30. 30 Pawloski CM, Eicker NM, Ball LM, Mangiapane ML, Fink GD. Effect of circulating vasopressin on arterial pressure regulation in rats. Am J Physiol 1989; 257:H209-H218.
31. 31 De Troyer A, Demanet JC. Clinical, biological and pathogenic features of the inappropriate secretion of antidiuretic hormone. O J Med 1976; 45:521-531.
32. 32 Huch KM, Runyan KR, Wall BM, Gavras H, Cooke CR. Hemodynamic response to vasopressin during V1-receptor antagonism in baroreflex-deficient subjects. Am J Physiol 1995; 268:R156-R163.
33. 33 Bakris G, Bursztyn M, Gavras I, Bresnahan M, Gavras H. Role of vasopressin in essential hypertension: racial differences. J Hypertens 1997; 15:545-550.
34. 34 Share L, Crofton JT, Ouchi Y, Vasopressin: sexual dimorphism in secretion, cardiovascular actions and hypertension. Am J Med Sci 1988; 295:314-319.
35. 35 Santucci A, Leonetti LR, Ferri C, Ficara C, Giarrizzo C, Balsano F. Relationship between vasopressin and the renin-angiotensin-aldosterone system in essential hypertension: effect of converting enzyme inhibitor on plasma vasopressin. J Hypertens 1985; 3 (suppl 2):S133-S134.